|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Journal of Clinical Virology
Volume 61, Issue 1 , Pages 55-60, September 2014
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus
Min-Min Yu
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Southeast University, Nanjing 210003, China
Corresponding Author author. Tel.: +86 13952040383; fax: +86 25 83468055.
Qian Jiang ,
Ying Ji ,
Kai-Hua Wu ,
Li-Li Ju ,
Xun Tang ,
Yong-Feng Yang
Received 28 March 2014; received in revised form 28 May 2014; accepted 3 June 2014. published online 16 June 2014.
Highlights
•The use of antiviral drugs in pregnancy.
•Telbivudine and lamivudine can reduce HBV DNA levels in pregnant women.
•Telbivudine and lamivudine can interrupt the vertical transmission of HBV.
Abstract
Background
Infection with hepatitis B virus (HBV) during pregnancy may lead to perinatal transmission.
Objectives
To compare the efficacy and safety of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
Study design
All pregnant women enrolled in this study were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Test patients underwent antiviral therapy with telbivudine or lamivudine while control patients received hepatitis B immune globulin (HBIG) injection.
Results
Patients in the telbivudine group had significantly lower HBV DNA and HBeAg levels and higher HBV DNA negative conversion rates compared to those in the lamivudine group before delivery. HBV DNA negative conversion rates in patients with abnormal alanine aminotransferase (ALT) levels were significantly higher than those in patients with normal ALT levels in the telbivudine and lamivudine groups before delivery. The intrauterine HBV infection rate and the percentage of immunization failure were both 0% in the telbivudine and lamivudine groups (χ2=0, 0; P=1, 1 respectively), compared to both 5% in the HBIG group (χ2=11.83, 7.86; P=0.002, 0.009 respectively). The side effects of three groups in mother and child were all unobvious.
Conclusions
Telbivudine and lamivudine can reduce HBV DNA levels in pregnant women, interrupt the vertical transmission of HBV and be used safely in mothers and children.
|
|
发表于 2014-9-17 21:36
